Advancements in Cardiac Amyloidosis Treatment
Recommended Citation
Arabi TZ, Shaik A, El-Shaer A, Al Tamimi O, Ahmed EN, Alabdaljabar MS, Safdar A, and Mushtaq A. Advancements in Cardiac Amyloidosis Treatment. Biomedicines 2024; 13(1).
Document Type
Article
Publication Date
12-31-2024
Publication Title
Biomedicines
Abstract
Cardiac amyloidosis (CA) is a progressive condition resulting from the deposition of amyloid fibrils in the heart, which leads to severe diastolic dysfunction and restrictive cardiomyopathy. The disease has two main subtypes: light-chain and transthyretin (TTR) CA, with the latter subdivided into wild-type and hereditary forms. Despite advances in diagnostic imaging, early detection remains a challenge due to non-specific symptoms that mimic other cardiac conditions. Treatment has evolved significantly with targeted therapies like TTR stabilizers, gene silencers, and RNA interference, showing promise in altering disease progression. However, barriers such as high costs, limited availability of genetic testing, and inadequate multidisciplinary care continue to impede comprehensive management. Future strategies should focus on integrating novel gene-editing therapies, expanding access to diagnostics, and enhancing multidisciplinary care models to improve outcomes. Overall, early diagnosis, equitable access to therapies, and personalized management plans are crucial to advancing care for CA patients.
PubMed ID
39857663
Volume
13
Issue
1
